Financing ·
Pulse Biosciences raises $95.8M via ATM and reports Q3 revenue of $0.4M
PLSEPulse Biosciences, Inc.
Pulse Biosciences raised $95.8 million in net proceeds through its at-the-market equity programs during the third quarter, bringing total capital raised since May to over $150 million with less than 6% dilution. The company reported Q3 revenue of $0.4 million and a GAAP net loss of $23.1 million. Cash and marketable securities totaled $189.2 million at quarter-end. Clinically, the firm completed enrollment in its U.S. pivotal IDE study for atrial fibrillation treatment three months ahead of schedule. Pulse Biosciences is a bioelectric medicine company developing nanosecond pulsed field ablation technology for cardiac and soft tissue treatments.